Summary
New platelet aggregation inhibitors in acute coronary syndrome in the emergency department
Velilla Moliner J, Povar Marco J, Gros Bañeres B, Santaló Bel M
Affiliation of the authors
Servicio de Urgencias, Hospital Universitario Miguel Servet, Zaragoza, España. Hospital de Sant Pau, Barcelona, Spain.
DOI
Quote
Velilla Moliner J, Povar Marco J, Gros Bañeres B, Santaló Bel M. New platelet aggregation inhibitors in acute coronary syndrome in the emergency department. Emergencias. 2013;25:58-65
Summary
New pharmacologic strategies for managing acute coronary syndrome (ACS) have
emerged in recent years. Clinical guidelines continue to recommend dual antiplatelet
therapy with aspirin and clopidogrel. Two recently approved P2Y12 inhibitors, prasugrel
and ticagrelor, have been shown to act faster and more effectively in treating ACS. These
drugs mark an important turning point in the emergency management of ACS. We
briefly review the pathophysiology of the thrombotic process and recall the early history
of antiplatelet therapy. We explain the results of clinical trials of these new drugs and
their use in the emergency department.